複雑性尿路感染症に対するCefmenoxime (CMX)の使用経験

概要

論文の詳細を見る
複雑性尿路感染症106例にcefmenoximeを投与した.1)総合臨床効果は82例中61例(74.4%)が著効ないし有効であり,膿尿に対する効果は53.2%,細菌尿に対する効果は58.5%であった.2)起炎菌95株の菌消失率は76.8%で,検出頻度の高かったSerratia 29株,Pseudomonas 13株の消失率はそれぞれ72.4%,53.8%であった.3)副作用は106例中3例に認めたが,いずれも一過性で,重篤ではなかったCefmenoxime (CMX) was intravenously administered to 106 patients with complicated urinary tract infection at a daily dose of 2-4 g for 5 days. An excellent response in overall clinical efficacy was seen in 15 cases (18.3%), a moderate response in 46 cases (56.1%) and poor response in 21 cases (25.6%). Pyuria was cleared in 20 cases (24.4%), decreased in 22 cases (26.8%) and unchanged in 40 cases (48.8%). Bacteriuria was eliminated in 41 cases (50.0%), decreased in 17 cases (20.7%), relapsed in 7 cases (8.5%) and unchanged in 17 cases (20.7%). Bacteriologically, 74 (76.8%) of the 95 strains isolated were eradicated by CMX, and 22 (23.2%) persisted. Side effects were observed in 3 (abdominal pain, diarrhea and elevation of trans amylase) of the 106 cases. Judging from the above results, CMX is considered to be a useful drug in the treatment of complicated urinary tract infections.